Karyopharm Therapeutics | KPTI - Assets


Karyopharm Therapeutics reported $131.42M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Abbott USD 110.43B 23.72B Mar/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Incyte USD 7.87B 533.53M Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Novartis USD 122.03B 3.5B Jun/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 201.13B 6.49B Jun/2026
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Takeda JPY 15.66T 210.16B Jun/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
TG Therapeutics USD 1.64B 110.79M Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026